All Dr Alyssa Johnsen articles
-
NewsEuropean Commission expands Dupixent approval in chronic spontaneous urticaria
New EU authorisation gives monoclonal antibody potential as new standard of care for the chronic skin condition.
-
NewsDupixent receives first-in-decade EU approval in chronic spontaneous urticaria
European approval of Sanofi and Regeneron’s monoclonal antibody provides eligible urticaria patients with a new first-line targeted treatment option.
-
NewsFDA approves novel therapy for chronic skin condition
The US approval could improve outcomes for eligible patients with previously limited options for managing the inflammatory skin condition.